FDA approves subcutaneous induction for AbbVie's Skyrizi in Crohn's disease
ABBV•The FDA approved subcutaneous induction dosing of AbbVie's Skyrizi for adults with moderately to severely active Crohn's disease. Patients can begin treatment at home with an on-body injector and continue maintenance dosing every eight weeks.
1. New dosing option
The FDA approved subcutaneous induction dosing of AbbVie's Skyrizi for adults with moderately to severely active Crohn's disease. The regimen allows patients to start treatment at home using an on-body injector, then continue maintenance dosing every eight weeks.
